James Halley

Jazz is paying $7.2 million to buy the maker of CBD-derived drug Epidiolex. Is it a smart deal?

These companies have awesome upside potential, and they won't break the bank

Pfizer already is putting its COVID-19 vaccine into people's arms, while Johnson & Johnson's is waiting to be approved.

Intuitive Surgical is down more than 7% since the start of this year. Does this present a buying opportunity or is it the harbinger of more bad news?

These three stocks all have solid dividend yields for income and expected growth -- just what you need to help fund your retirement.

These three healthcare stocks all had a good year in 2020, and their businesses look to have plenty of growth again in 2021.

Shares in this biotech company are down considerably from where they were this summer, but the stock looks ready to take off again.

These two inexpensive stocks pay surprisingly good dividends.

Buy these three biotech stocks before they take off.

With solid valuations and good dividends, these businesses will get you through the next rainy day -- or year.

These three small-cap stocks all turned a profit last quarter and present ample growth potential at bargain prices.

Johnson & Johnson and Pfizer are dependable stocks with good dividends, but they get little love from the market, making them bargains this year.

PerkinElmer's shares have risen more than 47% in 2020, so why isn't everyone talking about this fast-rising testing company?

Three stocks whose high-yield dividends aren't worth the risk.

Intuitive Surgical and Medtronic are involved in robotic-assisted surgery (RAS) systems, but Intuitive's shares have soared compared to the gains enjoyed by Medtronic's stock.

Whether or not you believe that Viatris can make you rich depends on how strongly you believe in biosimilars.

It's been a great ride for these three in 2020, but there are clouds on the horizon.

These three stocks can provide dividend investors with a solid and safe yield and consistent growth. And all three are available at a bargain, for the time being.

Plenty of companies did well in 2020 despite market dynamics connected to the coronavirus pandemic. Here's one that should fare particularly well in 2021.

Marijuana stocks are on an upswing, thanks to new states opening up to recreational and medical marijuana sales.